While our focus here has been on ALK TKIs, several studies have investigated antibody based approaches that target that ALK extracellular domain, which would be interesting to test in our ALKAL2‐driven NB models (Carpenter et al, 2012; Sano et al, 2019). The gene discussed is ALKAL2; the disease is neuroblastoma.